Sonoma Pharmaceuticals, Inc. announced that effective July 22, 2022, the Company's Board of Directors appointed Amy Trombly, Chief Executive Officer, to serve as a member of Board of Directors. Ms. Trombly will not receive additional compensation for her Board service. Ms. Trombly will serve as a Class I Director until the 2024 Annual Meeting of Stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4268 USD | +6.70% |
|
+66.01% | +136.59% |
07-09 | Sonoma Pharmaceuticals, Inc. Announces New Distributor in Ukraine | CI |
06-17 | Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+136.59% | 7.6M | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- SNOA Stock
- News Sonoma Pharmaceuticals, Inc.
- Sonoma Pharmaceuticals, Inc. Appoints Amy Trombly to Board of Directors